FDA Approves Viral Immunotherapy for Advanced Melanoma

Why it matters locally: The approval of this new immunotherapy offers a significant treatment option for Georgians battling advanced melanoma, particularly those for whom previous therapies have been ineffective. This could improve patient outcomes and potentially reduce the burden on healthcare facilities across the state.

---

WASHINGTON D.C. -- The U.S. Food and Drug Administration (FDA) today approved Tudriqev (vusolimogene oderparepvec-wtpg) for advanced melanoma. This approval specifically targets cases of the skin cancer that have not responded to prior treatments. Tudriqev is a genetically modified oncolytic viral therapy. It works by infecting and replicating within cancer cells, causing them to burst and release new viruses and tumor-associated antigens, which can then stimulate an immune response against the cancer.